標(biāo)題: Titlebook: New Approaches to Drug Discovery; Ulrich Nielsch,Ulrike Fuhrmann,Stefan Jaroch Book 2016 Springer International Publishing Switzerland 201 [打印本頁(yè)] 作者: 技巧 時(shí)間: 2025-3-21 16:49
書(shū)目名稱New Approaches to Drug Discovery影響因子(影響力)
書(shū)目名稱New Approaches to Drug Discovery影響因子(影響力)學(xué)科排名
書(shū)目名稱New Approaches to Drug Discovery網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱New Approaches to Drug Discovery網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱New Approaches to Drug Discovery被引頻次
書(shū)目名稱New Approaches to Drug Discovery被引頻次學(xué)科排名
書(shū)目名稱New Approaches to Drug Discovery年度引用
書(shū)目名稱New Approaches to Drug Discovery年度引用學(xué)科排名
書(shū)目名稱New Approaches to Drug Discovery讀者反饋
書(shū)目名稱New Approaches to Drug Discovery讀者反饋學(xué)科排名
作者: 魅力 時(shí)間: 2025-3-21 21:51 作者: Vo2-Max 時(shí)間: 2025-3-22 03:07 作者: Rejuvenate 時(shí)間: 2025-3-22 04:37
Derek S. Sim,Katalin Kausercorrelation function has been considered. Unfortunately, far from all encountered applied problems can be solved by correlation theory methods. A case in point is the problem of determining the probability that the ordinate of a random function will exceed a particular given value, which often arise作者: 令人悲傷 時(shí)間: 2025-3-22 09:12 作者: reptile 時(shí)間: 2025-3-22 16:54 作者: 斜 時(shí)間: 2025-3-22 18:40 作者: 牛的細(xì)微差別 時(shí)間: 2025-3-22 22:05 作者: Mucosa 時(shí)間: 2025-3-23 04:14 作者: 感激小女 時(shí)間: 2025-3-23 08:35 作者: hemoglobin 時(shí)間: 2025-3-23 12:58
Diana Behrens,Jana Rolff,Jens Hoffmannwith the problem discussed in Chapter 11.3 Comparison of Samples Series with Different Support, in particular the comparison between the grades of samples and the grades of the enclosing mining blocks (cf. Sect. 11.3.1). The economic implications of cut-off levels were discussed in Economic Evaluati作者: GORGE 時(shí)間: 2025-3-23 15:33
Daniela Fliegner,Christoph Gerdes,J?rg Meding,Johannes-Peter Staschwith the problem discussed in Chapter 11.3 Comparison of Samples Series with Different Support, in particular the comparison between the grades of samples and the grades of the enclosing mining blocks (cf. Sect. 11.3.1). The economic implications of cut-off levels were discussed in Economic Evaluati作者: ALLEY 時(shí)間: 2025-3-23 19:54 作者: 者變 時(shí)間: 2025-3-24 00:43 作者: 航海太平洋 時(shí)間: 2025-3-24 06:12 作者: Salivary-Gland 時(shí)間: 2025-3-24 07:06 作者: 無(wú)政府主義者 時(shí)間: 2025-3-24 13:49 作者: 危險(xiǎn) 時(shí)間: 2025-3-24 15:42
In Vivo Target Validation Using Biological Molecules in Drug Development,o testing of the therapeutic molecules in clinically relevant disease models can accelerate and significantly de-risk later stage clinical development. In this chapter, we will focus on (1) in vivo animal models and (2) pharmacological tools for target validation.作者: crutch 時(shí)間: 2025-3-24 21:41 作者: 不愿 時(shí)間: 2025-3-25 01:11 作者: Synthesize 時(shí)間: 2025-3-25 04:21
,New Compound Classes: Protein–Protein Interactions,physiology, targeted modulation of PPIs would tremendously extend the “druggable” genome. In fact, in every disease a wealth of potentially addressable PPIs can be found making pharmacological intervention based on PPI modulators in principle a generally applicable technology. An impressing number o作者: Urgency 時(shí)間: 2025-3-25 10:39 作者: 滔滔不絕的人 時(shí)間: 2025-3-25 14:56 作者: 多節(jié) 時(shí)間: 2025-3-25 18:19 作者: 痛恨 時(shí)間: 2025-3-25 23:52
Predictive In Vivo Models for Oncology,dels. The increasing knowledge about the heterogeneity of cancer requested a substantial restructuring of the test systems for the different stages of development. To be able to cope with the complexity of the disease, larger panels of patient-derived tumor models have to be implemented and extensiv作者: 光滑 時(shí)間: 2025-3-26 01:45 作者: 集聚成團(tuán) 時(shí)間: 2025-3-26 05:52
Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug operties of lead compounds with the ultimate goal to attain a clinical candidate which achieves a concentration–time profile in the body that is adequate for the desired efficacy and safety profile. A thorough characterisation of the lead compounds aiming at the identification of the inherent PK lia作者: FUME 時(shí)間: 2025-3-26 10:21
Nonclinical Safety and Toxicology,ntended use in humans. Hazards related to a drug have to be identified and the potential risks at the intended exposure have to be evaluated in comparison to the potential benefit of the drug. Preclinical safety is thus an integral part of drug discovery and drug development. It still causes signifi作者: IRATE 時(shí)間: 2025-3-26 12:43
Impact of Biomarkers on Personalized Medicine,endous impact on drug development. With the emergence of more sensitive and specific technologies that are now able to be run in clinical settings and the ability to accurately measure biomarkers, there is a need to understand how biomarkers are defined, how they are used in clinical trials, and mos作者: Definitive 時(shí)間: 2025-3-26 18:38
Modeling and Simulation of In Vivo Drug Effects,d development, and PK/PD modeling is common practice in all pharmaceutical companies. A recent analysis (Morgan et al., Drug Discov Today 17(9–10):419–424, 2012) revealed however that insufficient certainty in the integrity of the causal chain of fundamental pharmacological steps from drug dosing th作者: ALIBI 時(shí)間: 2025-3-26 23:47
Ulrich Nielsch,Ulrike Fuhrmann,Stefan JarochIn depth insights into drug discovery and early drug development.Latest technologies of target discovery and lead generation.New approaches to transfer drug candidates to clinical development作者: Scintigraphy 時(shí)間: 2025-3-27 03:29
Handbook of Experimental Pharmacologyhttp://image.papertrans.cn/n/image/664810.jpg作者: Notorious 時(shí)間: 2025-3-27 05:18
https://doi.org/10.1007/978-3-319-28914-4Biologics; Drug characterization; Drug discovery; Drug optimization; Drug targets; Preclinical research; M作者: 扔掉掐死你 時(shí)間: 2025-3-27 11:18 作者: saturated-fat 時(shí)間: 2025-3-27 13:50 作者: fulcrum 時(shí)間: 2025-3-27 18:40 作者: 文藝 時(shí)間: 2025-3-27 22:25
New Approaches to Drug Discovery978-3-319-28914-4Series ISSN 0171-2004 Series E-ISSN 1865-0325 作者: 前奏曲 時(shí)間: 2025-3-28 03:16
Book 2016mix of experts from academiaand industry give insight in selected new developments in the drug discoverypathway. The topics cover the different parts of the drug discovery process,starting with new developments in the target identification and validationarea. The lead generation part as a next step 作者: critic 時(shí)間: 2025-3-28 09:45
0171-2004 to transfer drug candidates to clinical development.This volume gives an overview ofstate of the art technologies and future developments in the field ofpreclinical pharmaceutical research. A balanced mix of experts from academiaand industry give insight in selected new developments in the drug disc作者: superfluous 時(shí)間: 2025-3-28 12:12 作者: minaret 時(shí)間: 2025-3-28 16:07
,New Compound Classes: Protein–Protein Interactions,f success stories in small-molecule PPI inhibition and natural-product PPI stabilization increasingly encourage academia and industry to invest in PPI modulation. In this chapter examples of both inhibition as well as stabilization of PPIs are reviewed including some of the technologies which has been used for their identification.”作者: 負(fù)擔(dān) 時(shí)間: 2025-3-28 18:54 作者: alabaster 時(shí)間: 2025-3-29 02:10
Functional Genomics in Pharmaceutical Drug Discovery,discussed with its advantages and challenges in this chapter. Furthermore the potential of CRISPR/Cas9, a gene-editing method that has recently been adapted for use as functional screening tool, will be briefly reviewed.作者: 規(guī)范要多 時(shí)間: 2025-3-29 06:11 作者: locus-ceruleus 時(shí)間: 2025-3-29 07:44 作者: HATCH 時(shí)間: 2025-3-29 12:28 作者: 偏狂癥 時(shí)間: 2025-3-29 15:36 作者: 非實(shí)體 時(shí)間: 2025-3-29 22:15 作者: 口訣法 時(shí)間: 2025-3-30 00:07 作者: ATOPY 時(shí)間: 2025-3-30 04:32 作者: CLASP 時(shí)間: 2025-3-30 10:56 作者: Wallow 時(shí)間: 2025-3-30 12:46
Translational In Vivo Models for Cardiovascular Diseases,neity of cardiac diseases plus the influence of genetic and environmental factors limit to mirror a particular disease with a single experimental model..Thus, drug development in the field of cardiology is not only very challenging but also inspiring; therefore animal models should be selected that 作者: V洗浴 時(shí)間: 2025-3-30 18:55
Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug by capturing target exposure or surrogates thereof and cellular mode-of-action readouts in vivo. Once robust PK/PD relationship in animal PD models has been constructed, it is translated to anticipate the pharmacologically active plasma concentrations in patients and the human therapeutic dose and d作者: Palpable 時(shí)間: 2025-3-31 00:09
Impact of Biomarkers on Personalized Medicine,r low. In the next following chapters, we will explain the various classifications of biomarkers, how they are applied, measured, and used in personalized medicine specifically focusing on how they are used in de-risking the 10 plus years drug development process and lastly how they are validated an作者: 拋媚眼 時(shí)間: 2025-3-31 04:52
Modeling and Simulation of In Vivo Drug Effects,tigation of the causality of drug responses is a major risk for translational assessments and the prediction of drug responses in different species or other populations. Mechanism-based modeling and simulation (M&S) offers a means to investigate complex physiological and pharmacological processes an作者: 持久 時(shí)間: 2025-3-31 06:24 作者: 使尷尬 時(shí)間: 2025-3-31 09:21
C. Ottmannr for which the expected loss (risk) Eown(Oj, 0), j = 1 or 2, is smallest is called the better with respect to Wn at point 0 (here EoO is the expectation evalua978-1-4899-0027-2Series ISSN 0172-4568 Series E-ISSN 2197-439X
